Fabio Ius1, Wiebke Sommer2, Igor Tudorache1, Christian Kühn1, Murat Avsar1, Thierry Siemeni1, Jawad Salman1, Michael Hallensleben3, Daniela Kieneke3, Mark Greer4, Jens Gottlieb5, Axel Haverich2, Gregor Warnecke6. 1. Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover. 2. Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover; German Centre for Lung Research, Hannover. 3. Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany. 4. Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany. 5. German Centre for Lung Research, Hannover; Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany. 6. Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover; German Centre for Lung Research, Hannover. Electronic address: warnecke.gregor@mh-hannover.de.
Abstract
BACKGROUND: The impact of early donor-specific anti-HLA antibodies (DSA) on patient and graft survival after lung transplantation remains controversial. In this study we analyzed risk factors for DSA that developed before initial hospital discharge after lung transplantation (early DSA) and compared mid-term outcomes in patients with or without DSA. METHODS: Between January 2009 and August 2013, 546 patients underwent lung transplantation at our institution. One hundred (18%) patients developed early DSA (Group A) and 446 (82%) patients (Group B) did not. Patient records were retrospectively reviewed. RESULTS: Retransplantation (odds ratio [OR] = 2.7, 95% confidence interval [CI] 1.1 to 6.5, p = 0.03), pre-operative HLA antibodies (OR = 2.1, 95% CI 1.2 to 3.4, p = 0.003) and primary graft dysfunction (PGD) score Grade 2 or 3 at 48 hours (OR = 2.6, 95% CI 1.5 to 4.6, p = 0.001) were associated with early DSA development. Overall, 1- and 3-year survival in Group A and B patients was 79 ± 4% vs 88 ± 2% and 57 ± 8% vs 74 ± 3%, respectively (p = 0.019). Eleven Group A (11%) and 32 Group B (7%) patients died before hospital discharge (p = 0.34). Among patients surviving beyond discharge, 1- and 3-year survival in Group A and B patients was 89 ± 4% vs 95 ± 1% and 65 ± 8% vs 80 ± 3% in Group A and B patients, respectively (p = 0.04). Multivariate analysis identified early anti-HLA Class II DSA (OR = 1.9, 95% CI 1.0 to 3.4, p = 0.04) as an independent risk factor for post-discharge mortality but not for in-hospital mortality. CONCLUSIONS: Pre-operative HLA antibodies, retransplantation or post-operative PGD increase the risk of developing early DSA, which were independently associated with an increased risk for mortality.
BACKGROUND: The impact of early donor-specific anti-HLA antibodies (DSA) on patient and graft survival after lung transplantation remains controversial. In this study we analyzed risk factors for DSA that developed before initial hospital discharge after lung transplantation (early DSA) and compared mid-term outcomes in patients with or without DSA. METHODS: Between January 2009 and August 2013, 546 patients underwent lung transplantation at our institution. One hundred (18%) patients developed early DSA (Group A) and 446 (82%) patients (Group B) did not. Patient records were retrospectively reviewed. RESULTS: Retransplantation (odds ratio [OR] = 2.7, 95% confidence interval [CI] 1.1 to 6.5, p = 0.03), pre-operative HLA antibodies (OR = 2.1, 95% CI 1.2 to 3.4, p = 0.003) and primary graft dysfunction (PGD) score Grade 2 or 3 at 48 hours (OR = 2.6, 95% CI 1.5 to 4.6, p = 0.001) were associated with early DSA development. Overall, 1- and 3-year survival in Group A and B patients was 79 ± 4% vs 88 ± 2% and 57 ± 8% vs 74 ± 3%, respectively (p = 0.019). Eleven Group A (11%) and 32 Group B (7%) patients died before hospital discharge (p = 0.34). Among patients surviving beyond discharge, 1- and 3-year survival in Group A and B patients was 89 ± 4% vs 95 ± 1% and 65 ± 8% vs 80 ± 3% in Group A and B patients, respectively (p = 0.04). Multivariate analysis identified early anti-HLA Class II DSA (OR = 1.9, 95% CI 1.0 to 3.4, p = 0.04) as an independent risk factor for post-discharge mortality but not for in-hospital mortality. CONCLUSIONS: Pre-operative HLA antibodies, retransplantation or post-operative PGD increase the risk of developing early DSA, which were independently associated with an increased risk for mortality.
Authors: Deepak K Nayak; Fangyu Zhou; Min Xu; Jing Huang; Moriya Tsuji; Jinsheng Yu; Ramsey Hachem; Andrew E Gelman; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar Journal: Sci Transl Med Date: 2017-07-12 Impact factor: 17.956
Authors: A A Abbas; J M Diamond; C Chehoud; B Chang; J J Kotzin; J C Young; I Imai; A R Haas; E Cantu; D J Lederer; K C Meyer; R K Milewski; K M Olthoff; A Shaked; J D Christie; F D Bushman; R G Collman Journal: Am J Transplant Date: 2016-11-04 Impact factor: 8.086
Authors: Elaine Y Cheng; Matthew J Everly; Hugo Kaneku; Nubia Banuelos; Laura J Wozniak; Robert S Venick; Elizabeth A Marcus; Suzanne V McDiarmid; Ronald W Busuttil; Paul I Terasaki; Douglas G Farmer Journal: Transplantation Date: 2017-04 Impact factor: 4.939
Authors: Ramsey R Hachem; Malek Kamoun; Marie M Budev; Medhat Askar; Vivek N Ahya; James C Lee; Deborah J Levine; Marilyn S Pollack; Gundeep S Dhillon; David Weill; Kenneth B Schechtman; Lorriana E Leard; Jeffrey A Golden; LeeAnn Baxter-Lowe; Thalachallour Mohanakumar; Dolly B Tyan; Roger D Yusen Journal: Am J Transplant Date: 2018-05-15 Impact factor: 8.086
Authors: Fabio Ius; Wiebke Sommer; Daniela Kieneke; Igor Tudorache; Christian Kühn; Murat Avsar; Thierry Siemeni; Jawad Salman; Carolin Erdfelder; Murielle Verboom; Jan Kielstein; Andreas Tecklenburg; Mark Greer; Michael Hallensleben; Rainer Blasczyk; Nicolaus Schwerk; Jens Gottlieb; Tobias Welte; Axel Haverich; Gregor Warnecke Journal: Transplantation Date: 2016-12 Impact factor: 4.939
Authors: Hrishikesh S Kulkarni; Kevin Tsui; Suraj Sunder; Alex Ganninger; Laneshia K Tague; Chad A Witt; Derek E Byers; Elbert P Trulock; Ruben Nava; Varun Puri; Daniel Kreisel; Thalachallour Mohanakumar; Andrew E Gelman; Ramsey R Hachem Journal: Am J Transplant Date: 2019-12-24 Impact factor: 8.086